Pharmaceutical company new drug/clinical news: JW Pharmaceutical Announcement of Empaguard diabetes treatment effect, etc.

JW Pharmaceutical announced on the 6th that it announced the results of the phase 3 clinical trial of 'Empaguard', a combination drug of type 2 diabetes treatment anagliptin (product name Guardret) and empagliflozin, at the recent European Diabetes Association conference. This clinical trial was conducted to evaluate the efficacy and safety of the Empaguard combination therapy group and the Empagliflozin combination treatment group. JW Pharmaceutical reported that the glycated hemoglobin level of the Empaguard treatment group decreased by 0.81% compared to before administration, showing a better blood sugar lowering effect than the control group's 0.24%. It was added that the rate of reaching the target blood sugar level was 55.7% in the Empaguard administration group, which was twice as high as the control group. In terms of safety, it was reported that the Empaguard treatment group showed a similar side effect rate to the control group.

Kwangdong Pharmaceutical announced on the 6th that it selected the group AKMU as the new model for 'Vita 500' and launched the 'Vita 500 AKMU Edition'. This edition includes 40 messages written by AKMU members Lee Chan-hyuk and Lee Su-hyun on the label. Kwangdong Pharmaceutical said that it selected Akmu as a model because its bright and positive image matched the Vita 500 brand.

HK Innoen announced on the 6th that its Chinese partner Cywind Bioscience announced the results of phase 1b clinical trials of 'Ecnoglutide', a glucagon-like peptide-1 (GLP-1) type obesity treatment drug, at the European Diabetes Association conference. In a clinical trial conducted on 48 obese Chinese adolescents, HK Innoen reported that the ecnoglutide treatment group showed a weight loss effect from 4 to 20 weeks. The treatment group lost 10.4 to 12.1% of body weight at week 20, but the placebo group gained 1.2%. The company explained that the treatment group also showed improvement in major cardiovascular and metabolic indicators, such as neutral fat and blood pressure, compared to the placebo group.

Yuhan Corporation announced that it will operate an exclusive booth at 'CPHI Worldwide 2026', which will be held in Milan, Italy from the 6th to the 8th of this month. Yuhan Corporation plans to promote its research and development (R&D) technology and commercialization capabilities to foreign pharmaceutical companies at this event.

HLB announced on the 6th that the U.S. Food and Drug Administration (FDA) classified the results of routine U.S. Good Manufacturing Practices (cGMP) inspections of China's Hengxi Pharmaceutical facility, which manufactures the finished product for the liver cancer drug 'rivoceranib', as a 'Voluntary Corrective Action Advisory' (VAI). HLB reported that VAI is granted when there are some issues, but the company is judged to be able to voluntarily correct them and no separate regulations are needed. HLB subsidiary Eleba Therapeutics is preparing the materials necessary to reapply for product approval together with Hangseo Pharmaceutical.

Dongwha Pharmaceutical announced on the 6th that its subsidiary Medisei's cervical intervertebral body fusion implant 'Nectune SA Cervical Cage' has obtained 510(k) certification from the U.S. FDA. It is known that this certification is granted after reviewing the actual equivalence of medical devices sold in the United States. MediSay plans to target the U.S. market in earnest starting next year after preparing for sales.

GC Green Cross announced on the 6th that it has launched 'Azelaheal Cream', an acne treatment product containing azelaic acid. Azelaic acid, the main ingredient developed by this company, can be used to treat various types of acne, including inflammatory acne.